Aviado · Research
Longevity Daily
Sunday, July 26, 2026
Listen
Today's Brief
Today's issue confronts the central paradox of modern longevity: a landmark Lancet study finds Americans spend 14 years in poor health at life's end — the worst morbidity gap globally — making healthspan the only number that actually matters. A single dose of rapamycin reverses autism-like traits in adult mice within hours, and SuperAgers prove genetically indistinguishable from average agers, pointing the spotlight firmly at lifestyle over genetics. An evidence check challenges the shingles vaccine's dementia-protection reputation, while a new Epigenomics analysis reveals your biological age score can vary by up to 45 years depending on which clock you use.
10 stories1 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
SuperAgers Can't Be Identified by Their Alzheimer's Genes — So What Sets Them Apart?
A new study found that people who maintain exceptional memory well into their 80s and beyond — known as SuperAgers — cannot be distinguished from cognitively average peers by APOE status or polygenic Alzheimer's risk scores, meaning low genetic risk doesn't guarantee SuperAging and high genetic risk doesn't rule it out. The findings shift scientific focus squarely onto lifestyle and environmental factors, since genetics alone cannot explain who achieves exceptional cognitive aging. If you carry an APOE4 variant, this is worth reading: your genes are not your cognitive destiny.
Read more →The Shingles Vaccine and Dementia: Why the Evidence Is Weaker Than Headlines Suggest
Physician-scientist Dr. Vinay Prasad has issued a detailed critique of the widely covered claim that the shingles vaccine reduces dementia risk, examining both the original Wales quasi-experimental study and newer observational data. His analysis argues that the evidence suffers from significant methodological limitations that haven't been adequately acknowledged — and that similar skepticism should apply to other vaccines promoted for cognitive protection. If the shingles shot is part of your cognitive strategy, this evidence check is essential reading before drawing firm conclusions.
Read more →One Dose of Rapamycin Reversed Autism Traits in Adult Mice — Within Hours
Scientists at UCLA administered a single dose of rapamycin to adult mice with autism-like traits and observed measurable behavioral reversal in approximately two hours, challenging the long-held belief that autism-associated brain changes are permanently locked in by adulthood. The rapid effect suggests functional brain plasticity remains accessible through mTOR pathway modulation, without requiring structural remodeling. Important caveat: this is a mouse study, and human translation is unproven — but the speed and reversibility of the effect have genuine implications for understanding how rapamycin acts on the brain.
Read more →Supplements & Compounds
Cognizin Citicoline Expands to New Markets, Backed by Research on Acute Cognitive Effects
Kirin Group and Blackmores are launching Cognizin Citicoline-based cognitive support supplements across Australia and New Zealand, citing recent research on the ingredient's acute performance effects. Citicoline (CDP-choline) has one of the stronger evidence profiles among nootropic compounds, with studies pointing to improvements in attention, focus, and memory formation. The geographic expansion signals growing commercial confidence in evidence-backed cognitive support ingredients as the global nootropics market matures.
Read more →Research & Papers
Americans Spend 14 Years in Poor Health — The Widest Morbidity Gap on Earth
A sweeping Lancet Public Health analysis tracking 204 countries from 1990 to 2023 found that the global gap between lifespan and healthy lifespan has grown from 8.8 to 10.7 years — and the United States fares worst among wealthy nations, with Americans averaging 14 years spent coping with chronic illness before death. The morbidity gap is driven by conditions like low back pain, depression, and diabetes — diseases that are largely preventable but rarely prioritized early enough. For longevity optimizers, this is the critical reminder that adding years to life without targeting healthspan is a failure mode, not a win. The data makes a compelling case for proactive, lifelong interventions — exercise, metabolic health, stress management — long before disease sets in.
Read more →Aviado Research: An Evidence-Based Deep Dive Into Longevity Science
This Aviado Research analysis examines the evolving science behind longevity interventions, separating well-supported findings from emerging hypotheses still awaiting rigorous validation. The focus, as always, is on translating complex research into actionable insight for readers committed to evidence-based health optimization.
Read the full Aviado analysis →Existing Drugs Already in Your Pharmacy May Slow Aging — Scientists Are Narrowing the List
Researchers are systematically screening already-approved medications — including rapamycin, metformin, and emerging senolytics — for evidence that they can slow biological aging in humans, with the goal of bypassing the decade-long timelines required for entirely novel drug development. Repurposed compounds come with existing safety profiles and regulatory histories, making them faster and cheaper to test in longevity contexts. For readers following the longevity pharmacology space, this overview offers a useful map of where the field's most credible near-term opportunities currently stand.
Read more →Your Biological Age Could Vary by 17 Years — Depending on Which Clock You Use
A new analysis published in Epigenomics tested eight different blood-based epigenetic aging clocks on the same samples and found an average spread of 17 years between the youngest and oldest predicted biological ages — with individual-level differences ranging from 4 to 45 years for the exact same person. The discrepancy reflects differences in how each model was trained, what cell types it measures, and how it defines aging — not any real difference in the person's biology. Before spending money on a biological age test, this paper is a necessary reality check: the number you get is highly dependent on which clock your provider happens to use.
Read more →Industry & Policy
FDA Clears 4 New Peptides — What the Evidence Says, and Who Was Voting
Four peptides have received FDA clearance, generating significant buzz in longevity and biohacking communities eager for new compounds to evaluate. A detailed breakdown examines the clinical evidence behind each newly approved peptide — and raises a pointed conflict-of-interest concern: some members of the FDA advisory panel reportedly hold financial stakes in the very compounds they voted to approve. Both the science and the disclosure issues deserve careful attention before anyone adds these compounds to their protocol.
Read more →RFK Jr. Pushes Alzheimer's Screening While Weakening the Panel That Could Drive It
Health Secretary RFK Jr. is calling for widespread Alzheimer's screening, but Columbia University researchers note there is currently no infrastructure — no standardized tests, no validated biomarkers — to support routine cognitive screening the way mammograms support breast cancer detection, with scientists still searching for markers that could flag cognitive change as early as ages 24–44. At the same time, the administration has reportedly moved to weaken the key independent panel that funds and coordinates screening and prevention research. Critics argue the political messaging is simultaneously inflating public expectations and undermining the scientific capacity needed to deliver.
Read more →